Ibio to begin trading on the nasdaq stock exchange

San diego, feb. 19, 2025 (globe newswire) -- ibio, inc. (nysea:ibio), an ai-driven innovator of precision antibody therapies, today announced that ibio's common stock has been approved for listing on the nasdaq capital market and ibio will transfer its stock exchange listing to nasdaq capital market from the nyse american. the company expects to begin trading as a nasdaq-listed company on mar 4, 2025, and will continue to trade under the symbol “ibio.” the company's common stock will continue to trade on the nyse american until the market close on mar 3, 2025.
NDAQ Ratings Summary
NDAQ Quant Ranking